Vanda Pharmaceuticals Inc. (VNDA)

22.79
0.22 0.97
NASDAQ : Health Technology
Prev Close 22.57
Open 22.75
Day Low/High 22.04 / 23.05
52 Wk Low/High 12.70 / 25.07
Volume 280.87K
Avg Volume 932.20K
Exchange NASDAQ
Shares Outstanding 52.45M
Market Cap 1.19B
EPS -0.30
P/E Ratio 94.25
Div & Yield N.A. (N.A)

Latest News

Vanda Receives FDA Letter Regarding Corporate Webpage

Vanda Receives FDA Letter Regarding Corporate Webpage

WASHINGTON, Nov. 1, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AZPN, COG, FBP, GCAP, SPSC, TWTR, USAK, VNDA Downgrades: ALK, CCK, CRM, EIGI, FBHS, GWRE, HOFT, HOPE, LAWS, LEG, MAS, MRVL, VREX, VTR, WRK Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Vanda Pharmaceuticals To Announce Third Quarter 2018 Financial Results On November 7, 2018

Vanda Pharmaceuticals To Announce Third Quarter 2018 Financial Results On November 7, 2018

Conference Call and Webcast to Follow

Vanda Pharmaceuticals Announces Participation At Oppenheimer And Cantor Fitzgerald Fall 2018 Investor Conferences

Vanda Pharmaceuticals Announces Participation At Oppenheimer And Cantor Fitzgerald Fall 2018 Investor Conferences

WASHINGTON, Sept. 26, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Rollins Set To Join S&P 500; Inogen To Join S&P MidCap 400; Vanda Pharmaceuticals And Garrett Motion To Join S&P SmallCap 600

Rollins Set To Join S&P 500; Inogen To Join S&P MidCap 400; Vanda Pharmaceuticals And Garrett Motion To Join S&P SmallCap 600

NEW YORK, Sept. 25, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: S&P MidCap 400 constituent Rollins Inc.

Vanda Announces Listing Of A New HETLIOZ® Patent In The FDA Orange Book

Vanda Announces Listing Of A New HETLIOZ® Patent In The FDA Orange Book

WASHINGTON, Sept. 20, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

HETLIOZ® (Tasimelteon) Driving Study Demonstrates No Impairment In Next Morning Performance

HETLIOZ® (Tasimelteon) Driving Study Demonstrates No Impairment In Next Morning Performance

WASHINGTON, Sept. 12, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Announces Participation At September 2018 Investor Conferences

Vanda Pharmaceuticals Announces Participation At September 2018 Investor Conferences

WASHINGTON, Sept. 4, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Vanda Wins Denial Of Petition For Rehearing On Fanapt®

Vanda Wins Denial Of Petition For Rehearing On Fanapt®

U.S. Court of Appeals Denies Petitions for Panel Rehearing and Rehearing En Banc

Vanda Pharmaceuticals Announces The Appointment Of General Counsel

Vanda Pharmaceuticals Announces The Appointment Of General Counsel

WASHINGTON, Aug. 13, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Reports Second Quarter 2018 Financial Results

Vanda Pharmaceuticals Reports Second Quarter 2018 Financial Results

- Total net product sales were $47.4 million in the second quarter of 2018

Vanda Pharmaceuticals To Announce Second Quarter 2018 Financial Results On August 1, 2018

Vanda Pharmaceuticals To Announce Second Quarter 2018 Financial Results On August 1, 2018

Conference Call and Webcast to Follow

Interesting VNDA Put And Call Options For August 17th

Interesting VNDA Put And Call Options For August 17th

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

Vanda Pharmaceuticals Announces Participation At June 2018 Investor Conferences

Vanda Pharmaceuticals Announces Participation At June 2018 Investor Conferences

WASHINGTON, June 1, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in June 2018: The Jefferies 2018 Global Healthcare Conference in New York...

VNDA Makes Notable Cross Below Critical Moving Average

VNDA Makes Notable Cross Below Critical Moving Average

In trading on Friday, shares of Vanda Pharmaceuticals Inc crossed below their 200 day moving average of $15.29, changing hands as low as $15.15 per share. Vanda Pharmaceuticals Inc shares are currently trading down about 1.9% on the day.

First Week of February 2018 Options Trading For Vanda Pharmaceuticals (VNDA)

First Week of February 2018 Options Trading For Vanda Pharmaceuticals (VNDA)

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.

Interesting VNDA Put And Call Options For January 2018

Interesting VNDA Put And Call Options For January 2018

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new January 2018 contracts and identified one put and one call contract of particular interest.

Relative Strength Alert For Vanda Pharmaceuticals

Relative Strength Alert For Vanda Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Vanda Pharmaceuticals Enters Oversold Territory (VNDA)

Vanda Pharmaceuticals Enters Oversold Territory (VNDA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Vanda Pharmaceuticals (VNDA) Shares Cross Below 200 DMA

Vanda Pharmaceuticals (VNDA) Shares Cross Below 200 DMA

In trading on Thursday, shares of Vanda Pharmaceuticals Inc crossed below their 200 day moving average of $15.26, changing hands as low as $14.65 per share. Vanda Pharmaceuticals Inc shares are currently trading off about 5.5% on the day.

Interesting VNDA Put And Call Options For November 17th

Interesting VNDA Put And Call Options For November 17th

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new November 17th contracts and identified one put and one call contract of particular interest.

Summit Therapeutics Stock Gets Smoked After IPO Pricing

Summit Therapeutics Stock Gets Smoked After IPO Pricing

Summit Therapeutics and Epizyme are raising cash to fund new drug development.

Vanda Pharmaceuticals (VNDA) Shares Cross Above 200 DMA

In trading on Tuesday, shares of Vanda Pharmaceuticals Inc crossed above their 200 day moving average of $15.01, changing hands as high as $15.30 per share. Vanda Pharmaceuticals Inc shares are currently trading up about 8.2% on the day.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ADGE, ANTX, HY, RTRX, VNDA Downgrades: CELP, FORD, GRC, HMSY, LNCE, MET, NCI, OUT, PLPC, UBA Initiations: ADAP, DGLT Read on to get TheStreet Quant Ratings' detailed report:

First Week of May 19th Options Trading For Vanda Pharmaceuticals (VNDA)

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new May 19th contracts and identified one put and one call contract of particular interest.

VNDA Makes Notable Cross Below Critical Moving Average

In trading on Monday, shares of Vanda Pharmaceuticals Inc crossed below their 200 day moving average of $14.20, changing hands as low as $14.10 per share. Vanda Pharmaceuticals Inc shares are currently trading off about 1.4% on the day.

VNDA Crosses Below Key Moving Average Level

In trading on Thursday, shares of Vanda Pharmaceuticals Inc crossed below their 200 day moving average of $13.75, changing hands as low as $13.55 per share. Vanda Pharmaceuticals Inc shares are currently trading off about 1.1% on the day.

First Week of April 21st Options Trading For Vanda Pharmaceuticals

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the April 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new April 21st contracts and identified one put and one call contract of particular interest.

TheStreet Quant Rating: B- (Buy)